Back to Search Start Over

Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis

Authors :
Roy Fleischmann
Michael E. Weinblatt
Michael Schiff
Harris A. Ahmad
Arnaud Constantin
Yannick Degboé
CHU Toulouse [Toulouse]
Université Toulouse III - Paul Sabatier (UT3)
Université Fédérale Toulouse Midi-Pyrénées
University of Colorado [Denver]
Brigham and Women's Hospital [Boston]
University of Texas Southwestern Medical Center [Dallas]
Bristol-Myers Squibb [Princeton]
Bristol-Myers Squibb
Source :
Journal of Clinical Medicine, Vol 9, Iss 2017, p 2017 (2020), Journal of Clinical Medicine, Journal of Clinical Medicine, MDPI, 2020, 9 (6), pp.2017. ⟨10.3390/jcm9062017⟩, Volume 9, Issue 6
Publication Year :
2020
Publisher :
MDPI AG, 2020.

Abstract

To date, the impact of background glucocorticoids (GC) on the efficacy and safety of abatacept or adalimumab in patients with active rheumatoid arthritis (RA) is not clearly established. This post hoc analysis of (AMPLE) trial (NCT00929864) compared efficacy and safety outcomes over 2 years in patients treated with abatacept or adalimumab plus background methotrexate (MTX), who continued GC (&le<br />10 mg/day) versus those who were not receiving GC (no-GC). Of 646 randomized patients, 317 received abatacept + MTX (161 GC, 156 no-GC) and 326 received adalimumab + MTX (162 GC, 164 no-GC). At Year 2, the adjusted mean changes from baseline in Disease Activity Score (DAS28 C-reactive protein (CRP)) and Health Assessment Questionnaire-Disability Index (HAQ-DI) were not significantly different in the GC versus no-GC subgroups receiving abatacept or adalimumab. A similar proportion of patients achieved remission, HAQ-DI score improvement &ge<br />0.3 and radiographic progression rates. No clinically meaningful safety differences were observed between GC versus no-GC subgroups either with abatacept or adalimumab. In patients with active RA of similar baseline disease activity treated with abatacept or adalimumab plus background MTX, there was no additional value of background GC on clinical, functional or radiographic outcomes over two years.

Details

Language :
English
ISSN :
20770383
Volume :
9
Issue :
2017
Database :
OpenAIRE
Journal :
Journal of Clinical Medicine
Accession number :
edsair.doi.dedup.....8c5882e9f8bb24ae52157c83c2e83bc2
Full Text :
https://doi.org/10.3390/jcm9062017⟩